Cargando…

A Proposal for a Comprehensive Grading of Parkinson's Disease Severity Combining Motor and Non-Motor Assessments: Meeting an Unmet Need

BACKGROUND: Non-motor symptoms are present in Parkinson's disease (PD) and a key determinant of quality of life. The Non-motor Symptoms Scale (NMSS) is a validated scale that allows quantifying frequency and severity (burden) of NMS. We report a proposal for using NMSS scores to determine level...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ray Chaudhuri, Kallol, Rojo, Jose Manuel, Schapira, Anthony H. V., Brooks, David J., Stocchi, Fabrizio, Odin, Per, Antonini, Angelo, Brown, Richard J., Martinez-Martin, Pablo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584126/ https://www.ncbi.nlm.nih.gov/pubmed/23468940 http://dx.doi.org/10.1371/journal.pone.0057221

Ejemplares similares

Correction: A Proposal for a Comprehensive Grading of Parkinson's Disease Severity Combining Motor and Non-Motor Assessments: Meeting an Unmet Need
por: Ray Chaudhuri, Kallol, et al.
Publicado: (2016)

Safinamide in the treatment pathway of Parkinson’s Disease: a European Delphi Consensus
por: Stocchi, Fabrizio, et al.
Publicado: (2022)

Distribution and impact on quality of life of the pain modalities assessed by the King’s Parkinson’s disease pain scale
por: Martinez-Martin, Pablo, et al.
Publicado: (2017)

Spotlight on non-motor symptoms and Covid-19
por: Rota, Silvia, et al.
Publicado: (2022)

Personalised Advanced Therapies in Parkinson’s Disease: The Role of Non-Motor Symptoms Profile
por: Leta, Valentina, et al.
Publicado: (2021)

The Dashboard Vitals of Parkinson’s: Not to Be Missed Yet an Unmet Need
por: Chaudhuri, Kallol Ray, et al.
Publicado: (2022)

Non-motor Parkinson's: integral to motor Parkinson's, yet often neglected
por: Todorova, Antoniya, et al.
Publicado: (2014)

Non motor symptoms in progressive supranuclear palsy: prevalence and severity
por: Radicati, Fabiana Giada, et al.
Publicado: (2017)

Opicapone versus placebo in the treatment of Parkinson’s disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial
por: Chaudhuri, K. Ray, et al.
Publicado: (2022)

Parkinson's Disease Subtypes Identified from Cluster Analysis of Motor and Non-motor Symptoms
por: Mu, Jesse, et al.
Publicado: (2017)

Parkinson's Disease and Post–COVID‐19 Syndrome: The Parkinson's Long‐COVID Spectrum
por: Leta, Valentina, et al.
Publicado: (2021)

Chaudhuri’s Dashboard of Vitals in Parkinson’s syndrome: an unmet need underpinned by real life clinical tests
por: Qamar, Mubasher A., et al.
Publicado: (2023)

Non-Motor Symptoms in Patients Suffering from Motor Neuron Diseases
por: Günther, René, et al.
Publicado: (2016)

The range and nature of non-motor symptoms in drug-naive Parkinson’s disease patients: a state-of-the-art systematic review
por: Zis, Panagiotis, et al.
Publicado: (2015)

Algorithms for the treatment of motor problems in Parkinson's disease
por: Dietrichs, E., et al.
Publicado: (2017)

Covid-19 and Parkinson's disease: Acute clinical implications, long-COVID and post-COVID-19 parkinsonism
por: Leta, Valentina, et al.
Publicado: (2022)

Characterization of Non‐Motor Fluctuations Using the Movement Disorder Society Non‐Motor Rating Scale
por: van Wamelen, Daniel Johannes, et al.
Publicado: (2022)

The Possible Clinical Predictors of Fatigue in Parkinson's Disease: A Study of 135 Patients as Part of International Nonmotor Scale Validation Project
por: Metta, Vinod, et al.
Publicado: (2011)

Reduced Effective Connectivity in the Motor Cortex in Parkinson’s Disease
por: Formaggio, Emanuela, et al.
Publicado: (2021)

Validation of the PD home diary for assessment of motor fluctuations in advanced Parkinson’s disease
por: Löhle, Matthias, et al.
Publicado: (2022)

COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson’s disease (PD): relevance for motor and non-motor features
por: Antonini, Angelo, et al.
Publicado: (2008)

A Consensus Set of Outcomes for Parkinson’s Disease from the International Consortium for Health Outcomes Measurement
por: de Roos, Paul, et al.
Publicado: (2017)

Motor and nonmotor complications in Parkinson’s disease: an argument for continuous drug delivery?
por: Chaudhuri, K. Ray, et al.
Publicado: (2013)

Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms Including Sleep: Results from a Meta-Analysis with 24-Month Follow-Up
por: Chaudhuri, K. Ray, et al.
Publicado: (2022)

Burden of non‐motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa‐carbidopa intestinal gel
por: Ray Chaudhuri, K., et al.
Publicado: (2018)

Asymmetric Dopamine Transporter Loss Affects Cognitive and Motor Progression in Parkinson's Disease
por: Fiorenzato, Eleonora, et al.
Publicado: (2021)

Opicapone as an Add-on to Levodopa in Patients with Parkinson’s Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial
por: Ferreira, Joaquim J., et al.
Publicado: (2022)

Rotigotine Transdermal Patch for Motor and Non-motor Parkinson’s Disease: A Review of 12 Years’ Clinical Experience
por: Raeder, Vanessa, et al.
Publicado: (2021)

Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson’s disease
por: Odin, Per, et al.
Publicado: (2018)

The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on ‘Off’-time in Patients with Advanced Parkinson’s Disease: A Systematic Review
por: Antonini, Angelo, et al.
Publicado: (2021)

Identifying Parkinson’s disease subtypes with motor and non-motor symptoms via model-based multi-partition clustering
por: Rodriguez-Sanchez, Fernando, et al.
Publicado: (2021)

Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease
por: Jost, Stefanie T., et al.
Publicado: (2021)

Coronavirus Disease 2019 and Related Parkinsonism: The Clinical Evidence Thus Far
por: Boura, Iro, et al.
Publicado: (2022)

Continuous Drug Delivery Aiming Continuous Dopaminergic Stimulation in Parkinson’s Disease
por: van Wamelen, Daniel J., et al.
Publicado: (2018)

Application of single wrist-wearable accelerometry for objective motor diary assessment in fluctuating Parkinson’s disease
por: Löhle, Matthias, et al.
Publicado: (2023)

The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II
por: Rocha, José-Francisco, et al.
Publicado: (2021)

The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II
por: Rocha, José-Francisco, et al.
Publicado: (2022)

Long-term effectiveness of levodopa-carbidopa intestinal gel on motor and non-motor symptoms in advanced Parkinson’s disease: results of the Italian GLORIA patient population
por: Antonini, Angelo, et al.
Publicado: (2020)

Infusion Therapies in the Treatment of Parkinson’s Disease
por: van Laar, Teus, et al.
Publicado: (2023)

Treatment paradigms in Parkinson's Disease and Covid-19
por: Boura, Iro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_05frajfv9dio70i9ie04ak275e